SHH-α and SHH-β, subtypes of SHH-MB by SNF, were enriched for MYCN amplification and were associated with worse survival outcomes [16] (five-year survival 69.8% and 67.3% for SHH-α and SHH-β, respectively vs. 88–88.5% for other SHH-MBs). This evidence concerns the gene SHH and Mobius syndrome.